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ABSTRACT
Objectives: Clinicians are told to use the number needed
to treat (NNT) to compare the beneﬁts of therapeutic
strategies, and researchers are asked to report results this
way, generally without considering differences among the
studies from which these were derived.
Methods: The crude NNT currently advocated is com-
pared to the NNT standardized for a common outcome,
follow-up time, study population and comparator. An
NNT  model  for  cardiovascular  disease  is  described  as
an example that addresses differences among studies of
secondary prevention of cardiovascular disease. Crude
NNTs  are  compared  to  those  obtained  from  the
model.
Results: Follow-up in the 18 trials identiﬁed varied from
1.0 to 6.2 years; rates of cardiovascular events in the
untreated subgroups ranged from 4.8% to 45.9%. The
crude NNTs were more variable (9.1–163.7) than those
obtained from the model (9.1–75.2). The effect of stand-
ardization was substantial in some cases, with propor-
tional changes ranging from a 91% decrease to a 223%
increase.
Conclusion: Using an NNT model to account for differ-
ences in study design allows for more meaningful
comparisons.
Keywords: number needed to treat (NNT), clinical deci-
sion making, cardiovascular disease.
Introduction
Proponents of “evidence-based medicine” strongly
advocate the use of randomized clinical trial results
to guide clinical practice, particularly for therapeu-
tic choices  [1].  These  trials  provide  estimates  of
the efﬁcacy of a speciﬁc, often novel, therapeutic
approach vis-à-vis placebo, “standard” therapy, or
another active comparator. Results are typically
reported using a relative measure of the effect (e.g.,
risk ratios, relative risk reduction), as such measures
are considered to be most generalizable from one
population to another [2]. These measures do not
provide guidance relative to health-care investments
as the impact on both health and costs depends on
the expected outcomes in the population of interest
when the intervention is not implemented. It is the
expected absolute effect (e.g., number of events pre-
vented in a deﬁned population over a speciﬁc period
of time) that is sought to inform decision-making.
The number needed to treat (NNT) has been
upheld as a measure of the absolute effect that is
easily understood by clinicians and decision-makers
alike [3–5]. The NNT is an estimate of the expected
number of patients who must be treated to avoid
one adverse event, and is appealing because it is per-
ceived to be simple and intuitive [4,6]. Intended to
provide a means for comparing the efﬁciency of
alternative therapeutic strategies—even across ther-
apeutic areas—the NNT has been designated the
“currency” of evidence-based medicine [7]. Calcu-
lating this “currency” is straightforward: it is the
reciprocal of the absolute risk reduction (i.e., the
difference between the risk of events in the reference
or control group and that in the intervention
group), usually obtained from a randomized clinical
trial [3].
Despite the apparent advantages, serious limita-
tions of the NNT have been pointed out [3,8,9].
These have mostly to do with the inability of the
NNT in its simplest form to account for differences
among the underlying trials (e.g., in duration of
follow-up, active vs. placebo comparators, end
points, and most importantly, reference event rates).
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Methods proposed to standardize the duration of
follow-up have required oversimpliﬁcations (e.g.,
constant hazard) [3,8] that may not be tenable and
introduce complexity to the calculation [10]; typi-
cally, without fully resolving the issues. Differences
in the baseline risk across trials are often insufﬁ-
ciently addressed [4] or simply ignored, as are the
other discrepancies. If the NNT is going to be used
as means of comparing interventions—and the cur-
rent tendency seems to be in that regard—then a
concerted effort must be made to ensure that bias
introduced by extraneous factors is removed as
much as possible. To address this, we propose using
an NNT model that permits estimation of the meas-
ure under identical conditions for all of the inter-
ventions at issue.
To demonstrate this approach, we present an
example comparing recently introduced medica-
tions for secondary prevention of cardiovascular
disease. Within the past decade, there has been tre-
mendous progress in this area. Collectively, cardio-
vascular disease therapies cover a broad spectrum
of distinct therapeutic areas. Common across all
types (e.g., antihypertensive agents vs. antiplatelet
agents) and stages (primary vs. secondary), how-
ever, the primary clinical objective remains the pre-
vention of events such as myocardial infarction
(MI), stroke, and cardiovascular disease death.
Methods
Derivation of  the Crude NNT
The crude NNT (cNNT) to prevent a single event
with a given treatment is calculated as the reciprocal
of the absolute reduction in risk of the event due to
the treatment. This can be derived as the difference
between the reference risk, that of the event in the
comparator, usually placebo, group (R0), and the
risk in the experimental group (R1). Equivalently,
the NNT can be obtained as the product of the pro-
portion of the reference risk that is prevented, the
relative risk reduction (RRR), and the risk of the
event in the comparator group. That is:
[1]
While the RRR can generally be assumed to be
applicable to different populations, R0 depends on
the type of population being studied, the length of
follow-up and, of course, on the end points it refers
to. Consequently, the cNNT from a given study will
also depend on the length of follow-up and refer-
ence risk, and is therefore not easily generalizable or
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directly comparable with those derived from other
studies.
NNT Model
To ensure that differences among the trials do not
bias comparisons of the NNT, it is necessary to cre-
ate an “NNT model.” This NNT model must be
capable of taking diverse inputs from the trials and
translating them to a standardized NNT (sNNT)
that purely reﬂects the drugs’ effects rather than dif-
ferences in the populations studied, the duration of
study, the end points measured or the comparators
that were used. Thus, the model has to simulate a
“standard” population receiving each of the drugs
for a standard period of time and compare the
results, measured using the same end points, to
what would have happened if this population had
been managed in some standard way instead. It is
also important in carrying out this simulation that it
properly reﬂects mortality from other causes in this
population if the time period is of any appreciable
length. Once the simulations are carried out, the
resulting “event rates” can be translated to the
sNNT using the same formula as for the cNNT.
For the example, we created an NNT model for
cardiovascular disease. This model is a modiﬁcation
of the Continuum of Risk Evaluation (CORE)
model, which has been described in detail elsewhere
[11]. CORE is a discrete event simulation of an indi-
vidual’s life in terms of cardiovascular disease given
each of the treatments at issue. The model allows
for analyses over the entire continuum of risk for
cardiovascular disease. The simulations are carried
out in two submodels. One submodel addresses pre-
vention before cardiovascular disease is present,
evaluating the transition from health to cardiovas-
cular disease (i.e., primary prevention); the other
deals with treatment of patients who already have
cardiovascular disease and evaluates the implica-
tions of additional events (i.e., secondary preven-
tion). The second submodel was used here. A
schematic representation of the model structure
modiﬁed for the NNT calculations is provided in
Fig. 1.
A discrete event simulation models the course
over time of “entities,” each of whom is assigned
speciﬁc values for a set of attributes. Applying the
risk of various events and then altering the
attributes and further risks as appropriate simulate
the course. The events and other outcomes (e.g.,
survival time) are counted in statistical accumula-
tors until the end of the time horizon. The entities
simulated in this model are individual patients with
pre-existing cardiovascular disease. Each patient is
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assigned attributes such as age and gender at the
start of the simulation based on prespeciﬁed distri-
butions. This assignment takes place by weighted
random sampling of the distributions. After assign-
ing relevant characteristics, the individual’s life is
simulated based on the risks they are expected to
face. To allow for complex risk functions (e.g., high
risk immediately after an event, then decreasing
with time since event, eventually increasing again
with age), the risks are considered in discrete time
intervals rather than seeking an analytic solution to
the risk equations and sampling the resulting cumu-
lative distribution of time to the next event. During
each interval, 1 month in this example, the patient
may experience one of three kinds of events: die of
noncardiovascular causes, die of cardiovascular
causes, or a nonfatal cardiovascular event (MI or
stroke). Deaths are assumed to occur at the begin-
ning of each interval, and if death does not occur,
the risks of nonfatal cardiovascular events are
applied. This hierarchy has little inﬂuence on the
results, however, because multiple events in a single
interval are very rare. In case of death from any
cause, the event is tallied and the patient is removed
from the simulation. If death does not occur, the
patient continues to cycle through the model for the
standard period of follow-up (i.e., the time hori-
zon). As the patient moves through the model, the
number and type of events, as well as their time of
occurrence, are tallied. The calculations are carried
out using a program written in Microsoft Visual
Basic 5.0.
For the NNT calculations, the model was modi-
ﬁed in several ways. The primary prevention sub-
model was removed as it was irrelevant. The
economic components of the model were also
removed for the same reason. The inputs were
changed so that the risks could be speciﬁed directly
instead of being derived from the patient’s
attributes. This was done because the distributions
of attributes could not be obtained from all the
studies in sufﬁcient detail and to avoid basing the
risk calculations only on the studies for which we
had risk equations. Thus, the risk of each type of
event is now an attribute of the patient and the user
can specify the source risk distributions directly.
Rather than calculate survival or quality-adjusted
life-year (QALY), this version of the model calcu-
lates the NNT at the end of each run.
Data Sources for the Example
The studies used to illustrate the use of the NNT
model were obtained by electronically searching the
medical literature (PubMed) to ﬁnd reports of clin-
ical trials of secondary prevention of cardiovascular
disease published in the Dutch, English, French,
German, Italian, or Spanish literature between Jan-
uary 1, 1995 and May 31, 2001, using the key-
words: stroke, MI, peripheral arterial disease,
peripheral vascular disease or prevention. The
abstracts of the articles identiﬁed in the search were
scanned to identify studies satisfying the following
criteria: randomized trial for antihypertensive,
antiplatelet or lipid-lowering therapy, with at least
1 year of treatment and follow-up, including only
subjects over 18 years of age, with pre-existing
cardiovascular disease, and reported outcomes
included at least one of MI, stroke or death. Studies
were excluded from review if the treatment involved
subcutaneous administration, sequential or switch-
ing therapeutic strategies, antidiabetic agents, diet
and exercise alone, dietary supplements, coronary
procedures, or were focused exclusively on special
populations such as patients with atrial ﬁbrillation.
This yielded a set of 18 studies [12–29].
Each article was reviewed to extract information
on: treatment(s) administered in experimental and
reference arms, sample size, length of follow-up,
speciﬁcs about the population under study (e.g.,
age, gender, clinical history of participants, etc.) and
total person-time accrued. For each relevant type of
event reported in the article, we also recorded what-
ever outcome measures were published: event
counts, risk, hazard, risk or hazard ratio, absolute
or relative reduction in risk, and coefﬁcients of
regression models.
To determine the cNNT to prevent an event,
deﬁned as an MI, a stroke or a cardiovascular
death, we required the risk of cardiovascular events
in the reference group and that in the experimental
group together with the period over which they
Figure 1 Schematic representation of  the NNT model for cardiovas-
cular disease outcomes. The model is a discrete event simulation. It
begins with the assignment to each individual of  the risks of  death and
of  cardiovascular events, depending on treatment. The course is then
modeled by considering whether an event occurs in each month until
the end of  the time horizon.
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were estimated. If these were reported directly, we
used them without modiﬁcation. Otherwise, we
derived the risks based on the event counts in each
arm over the course of the follow-up of each study.
While some studies reported the outcome cluster as
deﬁned (cardiovascular death, MI or stroke), others
reported each component separately and still others
reported some but not all of them. Thus, we were
obligated to reconstruct the necessary risks by
combining event counts from the individual
components.
To produce the sNNTs to prevent a cardiovascu-
lar event, the model needs an estimate of the treat-
ment effect measured as the hazard ratio relative to
placebo. These were obtained from the articles by
one of the following steps, in order of preference:
Adjusted hazard ratios from Cox proportional
hazards model were given highest priority, as these
are less biased than crude hazard ratios.
If the total person-time accumulated in each
treatment group was published along with the
number of events, the average hazards, and thus the
hazard ratio, were calculated.
If the risk ratio, or relative reduction in risk, was
provided, it was used as an estimate of the hazard
ratio.
In cases where none of the above measures were
reported, the event counts in each arm were used to
derive the risk ratio, to be used as an estimate of the
hazard ratio.
Where only an active comparator was studied
(i.e., there was no placebo arm), and thus the haz-
ard ratio relative to placebo could not be obtained
directly, this was derived using information external
to the trial following published methodology [30].
The relative risk reduction expected with the active
comparator relative to placebo documented in the
major published meta-analysis of randomized trials
[31] was used to estimate the “placebo” risk that
would have been observed if a placebo arm had
been included. The implied hazard ratio for the
treatment of interest was then calculated by divid-
ing its observed hazard by the derived “placebo”
one. As the difference in risk between any active
treatment and placebo tends to be larger than that
between active comparators, this derivation can
have quite an impact on the hazard ratio, and thus
on the NNT.
Standard Scenario
The common standard scenario used to estimate the
sNNT was deﬁned by ﬁve inputs: the risk (all
expressed as hazards) of noncardiovascular death,
the risk of a cardiovascular event (vascular death,
MI or stroke) in the absence of secondary pre-
vention, the  proportions  of  cardiovascular  events
of each type, the time horizon and the number of
patients to be simulated in each run. The risk of
noncardiovascular mortality was estimated at 80
deaths per 1000 person-years based on the “other
deaths” reported in the Cholesterol and Recurrent
Events (CARE) trial [23]. We used that trial because
we had access to patient-level data and could cal-
culate this directly as a monthly hazard and exam-
ine time-dependency [11] and its value was midway
between those reported in other trials. To estimate
the risk of cardiovascular events in the absence of
any of the treatments analyzed, the risks observed in
each of the placebo arms were examined. There
were clearly three clusters of studies: one group
experienced risk between 2.5% and 4% per year
(lower group); another (mid group) clustered
between 5% and 8% per year; and a third group
had risks above 11% per year (higher group). The
input for the standard scenario was set to 6.4% per
year, based on the average placebo event rate
observed in the studies in the mid group. To assess
the model’s sensitivity to this input, sNNTs were
also estimated based on the average risk in the
lower group (3.2% per year) and in the higher
group (13.6% per year). The proportions of cardi-
ovascular events of each type were set to 10.25%
vascular death, 79.50% MI, and 10.25% stroke
based on the average proportions in the mid group.
The simulation was run for a standard period of
3 years in 10,000 patients for each active arm of
each study.
Application of the NNT Model
Eighteen articles reporting on 16 different clinical
trials were reviewed (Table 1). The follow-up time
varied considerably, ranging from 1.0 to 6.2 years;
lipid-lowering therapy trials ran for about 5 years,
considerably longer than the antiplatelet and anti-
hypertensive therapy trials, which followed patients
for about 3 years. The study populations also dif-
fered between the trials; in some studies, partici-
pants were recruited immediately or soon after a
cardiovascular event [15,16,20], while in others,
patients were not eligible if they had experienced a
recent event (e.g., 14, 21, 22). Further, in some stud-
ies, patients underwent a revascularization proce-
dure before being randomized [13,28].
Differences in follow-up time and study popula-
tion are reﬂected in the risk of events observed in
the comparator arms of the trials (Table 2). The
lowest reference risk, 4.8% over 3 years, occurred
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in a study where some of the participants received a
percutaneous transluminal coronary angioplasty
(PTCA) or coronary artery bypass grafting (CABG)
immediately after their qualifying event [28]. The
highest risk, 45.9% over 3.1 years, was in the pla-
cebo arm of a study where participants were
recruited within a week of an MI and were suffering
left ventricular dysfunction [15].
The cNNT to prevent a cardiovascular event
ranged from 9.1 for pravastatin in the older (65–
75 years of age) subgroup of the CARE study [24]
to 163.7 for quinapril in the Quinapril Ischaemic
Event Trial (QUIET) study [13]. The cNNTs were
highly variable even within the three therapeutic
groups: the values ranged from 11.3 to 163.7 for
antihypertensive treatment studies, 10.9 to 115.4
for antiplatelet treatment studies and 9.1 to 58.9 for
lipid lowering treatment studies.
The sNNTs for preventing a cardiovascular event
based on the standard scenario present a very dif-
ferent picture (Fig. 2, Table 3). The values were far
less variable, ranging from 9.1 [19] to 75.2 [22].
Several of the NNTs changed substantially from
their crude values. In the clopidogrel versus aspirin
in patients at risk of ischaemic events (CAPRIE)
study [16], for example, where the comparator arm
was treated with aspirin, in effect creating a lower
risk comparator population, the NNT for clopidog-
rel dropped from 115.4 to 10.7, an 91% decrease.
Similar decreases were observed in the QUIET study
[13], the Syst-Eur study [14], and the Regression
Growth Evaluation Statin Study (REGRESS) [28],
all of which had lower reference risks and follow-up
of about 2 years. A large decrease was also seen in
the Ishikawa study [19], but it was made more
substantial, despite a higher reference risk, because
the  follow-up  time  was  much  shorter,  just  1 year.
By contrast, studies with long follow-up times
tended to have increases in NNT once it was stand-
ardized [21,24,26,29]. By the same token, the NNT
Table 1 Description of  clinical trials reviewed: intervention, mean length of  follow-up, reference population and reported
outcomes
Trial Treatment Comparator N
Follow-up
(year)
Mean
age Selection factors
Reported 
outcomes
HOPE [12] Ramipril Placebo 9,297 5.0 66 CAD, CVA or PAD. 1,2,3
QUIET [13] Quinapril Placebo 1,750 2.3 58 No MI in 7 days prior or
PTCA in 3 months
PTCA at baseline
1b,2
Syst-Eur [14] Nitrendipine Placebo 4,695 2.0 70 No prior CVA and no
MI in year prior
1,2,3
TRACE [15] Trandolapril Placebo 1,749 3.1 67 MI in 6 prior days + LVD 1,2
CAPRIE [16] Clopidogrel ASA 19,099 1.9 63 CVA in prior 6 months
or MI within 35 days,
or PAD
1,2,3
ASA study
group [17]
ASA Nicametate 466 1.7 63 CVA but no MI within
6 weeks. Atrial 
ﬁbrillation excluded
1c,2,3
ESPS2 [18] ASA,
dipyridamole
Placebo 6,602 2.0 67 TIA or CVA within
3 months
1d,3
Ishikawa [19] Aspirin, ticlo
dipyridamole
Placebo 1,083 1.0 60 MI ≥ 8 days prior 1b,2
JAMIS [20] ASA,trapidil Placebo 723 1.3 65 MI in month prior 1,2,3,4
4S [21] Simvastatin Placebo 4,444 5.4 ≥60* Angina or
MI ≥ 6 months prior
1b,2
BIP [22] Bezaﬁbrate Placebo 3,090 6.2 60 Angina or
MI ≥ 6 months prior
1b,2,3
CARE [23] Pravastatin Placebo 4,159 5.0 59 MI ≥ 3 months prior 1b,2,3
CARE [24] Pravastatin Placebo 1,283 5.0 54 MI ≥ 3 months prior,
age ≥ 65 year
1b,2,3
CARE [25] Pravastatin Placebo 576 5.0 61 MI ≥ 3 months prior,
female
1b,2,3
LIPID [26] Pravastatin Placebo 9,014 6.1 62† MI ≥ 3 months prior 1b,2,3
PLAC [27] Pravastatin Placebo 559 3.0 58 Patients with known CAD 1b,2
REGRESS [28] Pravastatin Placebo 884 2.0 56 MI ≥ 8 weeks, no PTCA,
CABG in year. PTCA,
CABG for index MI ok.
1b,2,3,5
Rubins [29] Gemﬁbrozil Placebo 2,531 5.1 64 CHD history but no
other conditions.
1b,2,3
*Exact mean age not reported.
†Reported as median age.
Abbreviations: CABG, coronary artery bypass grafting; CAD, coronary artery disease; CHD, coronary heart disease; CVA, cerebrovascular accident; MI, myocardial
infarction; PAD, peripheral arterial disease; PTCA, percutaneous transluminal coronary angioplasty; TIA, transient ischaemic attack; 1, vascular death; 1b, cardiac death;
1c, fatal MI or fatal stroke; 1d, all-cause death; 2, non-fatal MI; 3, non-fatal stroke; 4, angina; 5, TIA.
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for trandolapril in the trial Trandolapril Cardiac
Evaluation (TRACE) study [15], which was in the
higher risk group (very recent event), increased
from 11.3 to 36.5, a threefold rise. A higher risk in
the reference population was also responsible for
increases in sNNT in the European stroke preven-
tion study (ESPS) arms [18].
To assess the sensitivity of the model to the ref-
erence risk being employed, we ran the NNT model
using two alternative risk levels, keeping all other
factors the same. While the values of the NNT
changed considerably when the reference risk was
altered, the rankings were only slightly affected
(Table 3). When the reference risk was set to the
Table 2 Crude risk of  events in experimental and comparator groups, crude NNT and hazard ratios for each active treatment
arm of  the studies
Trial name
Experimental Comparator
Crude NNT* Hazard ratioEvents Risk (%) Events Risk (%)
HOPE [12] 651 14.0 826 17.8 26.7 0.78†
QUIET [13] 48 5.5 53 6.1 163.7 0.91‡
Syst-Eur [14] 121 5.0 165 7.2 46.8 0.70‡
TRACE [15] 325 37.1 401 45.9 11.3 0.81§
CAPRIE [16] 939 9.8 1021 10.7 115.4 0.91†
ASA study [17] 19 8.6 34 13.9 18.6 0.63‡
ESPS2 [18] (ASA arm) 320 20.0 378 22.9 34.4 0.87§
ESPS2 [18] (Dipyridamole) 321 19.4 378 22.9 28.4 0.85§
ESPS2 [18] (ASA + dipyridamole) 286 17.3 378 22.9 17.9 0.76§
Ishikawa [19] 14 2.3 30 6.5 23.9 0.35§
JAMIS [20] (ASA arm) 36 14.4 42 18.3 25.9 0.74‡
JAMIS [20] (Trapidil arm) 22 9.1 42 18.3 10.9 0.47‡
4S [21] 431 19.4 622 28.0 11.7 0.69§
BIP [22] 304 19.6 329 21.3 58.9 0.92§
CARE [23] 266 12.8 352 16.9 24.1 0.75§
CARE – older patients [24] 120 18.8 191 29.7 9.1 0.63§
CARE – female patients [25] 30 10.5 55 19.0 11.8 0.55§
LIPID [26] 726 16.1 919 20.4 23.1 0.79§
PLAC I & II [27] 14 5.0 29 10.4 18.4 0.48§
REGRESS [28] 12 2.7 21 4.8 46.0 0.55§
Rubins HB et al. [29] 258 20.4 330 26.1 17.7 0.76†
*Due to rounding, the crude NNT reported in the article may not match the values calculated using the risks in this table.
†Adjusted hazard ratio (from Cox proportional hazards model).
‡“Crude” hazard ratio either reported directly in article or derived using event counts and total person-time accrued in each arm.
§“Crude” risk ratio either reported directly in article or derived using event counts and number of  patients randomized to each arm.
Figure 2 Scatter plot of  standardized
NNTs (moderate risk) vs. crude NNT.
Points below the diagonal line indicate that
the standardized value is below the crude
one; above the line, the standardization
raised the value.Crude NNT
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average from the lower group of studies (3.2% per
year), half of the that in the standard scenario, the
NNTs increased proportionally (roughly doubled);
similarly, when the model was run with the average
reference risk from the higher group (13.6% per
year), the resulting sNNTs were roughly half those
obtained at the moderate risk level.
Discussion
The NNT methodology cannot be endorsed to cre-
ate league tables to compare interventions, particu-
larly as the sole basis for decision-making. They
oversimplify and can considerably mislead. Due to
this very oversimpliﬁcation, however, the NNT has
gained increasing acceptance and endorsement as
the “simple currency” of evidence-based medicine
[4,6,7]. Thus, if it is going to be invoked as the
means for comparison and decision-making, the
NNT must be adjusted for differences in patient
populations, length of follow-up, comparators, etc.
As demonstrated in the example developed in
this article, the crude NNT calculated based directly
on the published trial results is subject to extrane-
ous features of the trial design, or even of the pub-
lication itself, that do not have anything to do with
the intervention’s effect per se. Indeed, the cNNT
consistently under- or overestimated the standard-
ized NNT, often by a magnitude of 20% or more of
the crude estimate and upwards of 100% in one
case. Further, the rank of one therapy relative to the
others’—typically utilized by decision-makers to
create “league tables”—was strongly dependent on
whether the discrepancies among studies were taken
into account in the calculation of the NNT.
Limitations of the NNT measure have been rec-
ognized in the literature and several corrective
methods have been proposed. For instance, it was
suggested that the NNT be adjusted to a different
baseline risk using a simple multiplicative factor [4],
assuming that the observed relative risk reduction is
constant across different populations. Others [8,10]
have described ways of adjusting the NNT to dif-
ferent lengths of follow-up time based on the use of
hazards rather than risks or the full “survival”
curves rather than the cumulative risk during the
study. None of the proposed methods, however,
address all of the problems. The NNT model pro-
posed in this article handles both issues simultane-
ously and further incorporates a competing risk of
death from noncardiovascular causes, which is rel-
evant in the context of chronic outcomes. Although
this is no longer a straightforward, simple way to
calculate the NNT, the easy method leads to biased
estimates introduced by factors impervious to the
intervention. A simple adjustment would be sufﬁ-
Table 3 Standardized NNTs and corresponding rank for lower (3.2% per year), mid (6.4% per year) and higher (13.2% per year)
risk levels
Trial name
Reference risk
Lower Mid Higher
NNT Rank NNT Rank NNT Rank
HOPE [12]* 51.0 15 27.2 15 14.8 15
QUIET [13]* 138.9 20 64.5 20 35.5 20
Syst-Eur [14]* 35.5 7 19.3 7 10.6 7
TRACE [15]‡ 69.0 17 36.5 17 19.9 17
CAPRIE [16]† 35.8 8 19.4 8 10.7 8
ASA study group [17]† 44.8 11 24.9 11 13.4 11
ESPS2 [18] (ASA)‡ 106.4 19 54.6 19 28.9 19
ESPS2 [18] (Dipyridamole)‡ 89.3 18 45.7 18 23.3 18
ESPS2 [18] (ASA + dipyridamole)‡ 50.3 14 27.0 14 14.6 14
Ishikawa [19]† 17.6 1 9.1 1 4.8 1
JAMIS [20] (ASA)‡ 47.6 13 26.0 13 14.0 13
JAMIS [20] (Trapidil)‡ 3.2 3 12.2 3 6.5 3
4S [21]† 36.0 9 19.4 8 10.7 9
BIP [22]* 169.5 21 75.2 21 41.7 21
CARE [23]* 44.1 10 24.4 10 13.1 10
CARE – older patients [24]† 29.5 6 16.1 6 8.9 6
CARE – female patients [25]* 25.1 5 13.3 5 7.1 5
LIPID [26]* 53.5 16 28.2 16 15.4 16
PLAC I & II [27]* 21.6 2 11.4 2 6.0 2
REGRESS [28]* 24.6 4 13.1 4 7.0 4
Rubins [29]† 45.7 12 25.3 14 13.7 12
*The rates (hazard) of  events in the placebo group of  these studies were averaged to derive a value to represent a “Lower” risk level to be used in the model.
†The rates (hazard) of  events in the placebo group of  these studies were averaged to derive a value to represent a “Mid” risk level to be used in the model. In the case
of  the two active comparator studies (CAPRIE [16] and ASA Study Group [16]), the rates in the comparator groups were ﬁrst adjusted to reﬂect the expected rate
in a placebo group, using methods described by Fisher et al. [30].
‡The rates (hazard) of  events in the placebo group of  these studies were averaged to derive a value to represent a “Higher” risk level to be used in the model.
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cient to inform rational decision-making only when
all other aspects are already standardized or not an
issue. For example, if the condition is acute and has
no sequelae, thus eliminating follow-up time, there
is a single agreed-upon outcome, and there is a
common comparator, then differences in baseline
risk can be corrected for using a simple ratio [4].
Needless to say, this is a very unusual situation.
Thus, although the choice of methodology should
always be guided by pursuit of simplicity, with
respect to the NNT this will nearly always lead to
errors.
The methodology we propose is not without lim-
itation. A model cannot easily resolve the problem
of comparing across therapeutic areas—how does
one value lipid lowering therapy following a MI rel-
ative to chemotherapy in a patient with cancer?
This requires the identiﬁcation of a common end
point and the only candidate—death—does not nec-
essarily reﬂect the beneﬁts of an intervention and
would favor some diseases over others. The other
option, which has been proposed [32], the NNT to
gain one QALY is also based on survival and suffers
from additional methodological problems, but, in
any case, also demands the use of a model to derive
it. In any case, a common outcome must be chosen
and, as the trials are unlikely to be redone, it must
be chosen with a view to providing as much balance
as possible—it needs to reﬂect the “average” out-
come in some sense.
Perhaps more challenging for the user is the
creation of a standard scenario. In the absence of
agreed-upon standards, the researcher is left to cre-
ate their own scenario and this raises the possibility
of multiple standards and opens the methodology
up to tailoring of the “standard” to highlight the
beneﬁts of one therapy over another. At this point,
the minimum requirement would be that NNTs be
compared only if estimated using a common stand-
ard and that in any such comparisons the standard
be fully speciﬁed. At least this way the consumers of
the information will be aware of inputs that may be
generating differences and can assess the appropri-
ateness of the proposed standard. There may even
be situations where despite similarities in indica-
tion, the standards necessarily differ because the
target populations are dissimilar. In that circum-
stance though, NNTs should not be compared or
these contrasts must done with extreme caution and
full disclosure of the differences in inputs.
An even more difﬁcult problem would arise if
there were variation in the relative risk reduction
depending on the level of baseline risk. No correc-
tion of the NNT can account for this without
empiric evidence of the degree of dependency and
this is rarely available as the studies are not typically
powered for such subgroup analyses nor repeated in
populations at other levels of risk. The assumption
that the relative, but not the absolute, risk reduction
observed in a randomized clinical trial can be gen-
eralized to populations at other levels of risk is not
unique to the sNNT—it provides the fundamental
basis for our belief in the usefulness of the clinical
trial. If this belief were demonstrated to be untena-
ble, it would be necessary to carry out separate tri-
als in each and every population of interest and, of
course, the NNT calculations would have to be per-
formed accordingly.
Another limitation, present also with the cNNT,
is the assessment of the precision of the estimates. A
95% conﬁdence interval can be generated but it is
problematic because it can lead to negative, or even
inﬁnite, NNTs when the effect estimates overlap the
null point. Thus, these do not behave as standard
conﬁdence intervals and are not readily interpreta-
ble. With the sNNT, available techniques for assess-
ing uncertainty in models could be employed (e.g.,
sensitivity analysis, bootstrapping) but these gener-
ally depend on some sense of what the “threshold
value” is and no such value has been deﬁned for the
NNT.
Acknowledging the need for meaningful evi-
dence-based information to inform clinical practice
and the widespread embracing of these ideas in aca-
demic medicine, we must ensure that the estimates
used to draw conclusions are determined in the least
biased way possible. The randomized clinical trial
helps ensure this for the relative risk reduction. It is
important that similar consideration be given to the
factors that inﬂuence, and potentially bias, the
NNT. The commonly present extraneous factors
that alter the NNT must be taken into account and
to do this, we advocate the development and imple-
mentation of a model to calculate a standardized
NNT.
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